• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Readout Health Announces Clinical Partnership with Apollo Health for the Management of Neurodegenerative Disease

Share:

November 17, 2020

Readout Health, a digital biomarker startup, announced today its partnership with Apollo Health, a health technology leader in neurodegenerative medicine. Apollo Health has created the first online community of specially trained healthcare practitioners and participants partnering to use a science-based protocol demonstrated to prevent and reverse cognitive decline. As part of its program, Apollo Health recommends nutritional ketosis and the KetoFLEX 12/3 diet developed by noted neurologist and Alzheimer’s researcher Dr. Dale Bredesen and the team at Apollo Health.

Readout Health’s flagship product, BIOSENSE™, is a non-invasive clinical-grade breath ketone monitoring solution. A recent peer-reviewed publication outlined the clinical trial of BIOSENSE in tracking all-day ketosis and highlighted the requirement for more frequent measurements for accurate and personalized metabolic responses. BIOSENSE is a handheld breath meter, classified as an FDA Class 1 medical device, manufactured in St. Louis. Readout Health patented a deep lung sampling process to secure strong acetone concentrations in breath for a high level of clinical accuracy to use as an alternative to blood BHB measurements. Designed for unlimited measurements for stronger resolution, BIOSENSE™ is currently used in several protocols for in-home testing and qualifies for remote patient monitoring (RPM) reimbursement. The partnership will include BIOSENSE™ measurements and trends to be integrated into Apollo’s ReCODE mobile application.

“Dr. Bredesen and team are pioneers in novel approaches to neurodegenerative diseases. We are committed and BIOSENSE is uniquely positioned to bring transparency to both participants and their care teams for stronger adherence and better outcomes,” according to Jim Howard, Readout CEO. “This represents strategic progress in our goal to support the research of therapeutic nutritional ketosis research in chronic disease management.”

“We’re excited to announce our partnership and sincerely hope that the BIOSENSE Breath Ketone Meter will offer participants an easier and more accurate way to track ketones, ensuring better compliance with the protocol,” said Dr. Dale Bredesen, Chief Science Officer of Apollo Health.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Global Flow Cytometry Services Market worth $ 1.5 Billion by 2030 – Exclusive Report by InsightAce AnalyticGlobal Flow Cytometry Services Market worth $ 1.5 Billion by 2030 – Exclusive Report by InsightAce Analytic
  • Lyra Health Reaches $1.1B Valuation After $110M Series D to Meet Demand for TeletherapyLyra Health Reaches $1.1B Valuation After $110M Series D to Meet Demand for Teletherapy
  • Amyris to Acquire EcoFabulous Clean Beauty Brand Focused on Fast-Growing Gen Z Consumer SegmentAmyris to Acquire EcoFabulous Clean Beauty Brand Focused on Fast-Growing Gen Z Consumer Segment
  • ANEW MEDICAL, INC. Acquires World Wide License to Treat Neurodegenerative Diseases Using a Longevity Protein and Gene Therapy Programs.ANEW MEDICAL, INC. Acquires World Wide License to Treat Neurodegenerative Diseases Using a Longevity Protein and Gene Therapy Programs.
  • Teva up 2% on possible sales of Medis unitTeva up 2% on possible sales of Medis unit
  • Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cashRoche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash
  • Philips Rolls Out Mobile ICUs in India to Tackle COVID-19, Can Be Deployed in 1 DayPhilips Rolls Out Mobile ICUs in India to Tackle COVID-19, Can Be Deployed in 1 Day
  • Bausch Health Acquires Eton Pharmaceuticals’ EM-100 Investigational Eye Drop For The Treatment Of Itchy Eyes Associated With AllergiesBausch Health Acquires Eton Pharmaceuticals’ EM-100 Investigational Eye Drop For The Treatment Of Itchy Eyes Associated With Allergies

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications